Additionally, the 36-month beta value for PYXS is 1.13. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PYXS is 44.02M and currently, short sellers hold a 14.04% ratio of that float. The average trading volume of PYXS on July 03, 2025 was 564.57K shares.
PYXS) stock’s latest price update
Pyxis Oncology Inc (NASDAQ: PYXS)’s stock price has plunge by 11.11%relation to previous closing price of $1.08. Nevertheless, the company has seen a -6.25% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-30 that BOSTON, June 30, 2025 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 246,238 shares of Pyxis Oncology’s common stock to four newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan (the ‘Plan’) with a grant date of June 30, 2025, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
PYXS’s Market Performance
PYXS’s stock has fallen by -6.25% in the past week, with a monthly drop of -1.64% and a quarterly rise of 31.15%. The volatility ratio for the week is 10.02% while the volatility levels for the last 30 days are 7.26% for Pyxis Oncology Inc The simple moving average for the last 20 days is -1.64% for PYXS stock, with a simple moving average of -36.93% for the last 200 days.
Analysts’ Opinion of PYXS
Stephens, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $13. The rating they have provided for PYXS stocks is “Overweight” according to the report published on November 08th, 2024.
Stifel gave a rating of “Buy” to PYXS, setting the target price at $10 in the report published on August 08th of the previous year.
PYXS Trading at 1.92% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.74% of loss for the given period.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -31.38 for the present operating margin
- 0.33 for the gross margin
The net margin for Pyxis Oncology Inc stands at -27.99. The total capital return value is set at -0.88. Equity return is now at value -66.30, with -53.49 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.0.
Currently, EBITDA for the company is -65.51 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 23.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.75.
Conclusion
In conclusion, Pyxis Oncology Inc (PYXS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
